Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia

Emily Huscharta Phoenix Children’s Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA

Holly Millera Phoenix Children’s Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA;b Mayo Clinic Arizona, Phoenix, Arizona, USA

Dana Salzberga Phoenix Children’s Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA

Courtney Campbella Phoenix Children’s Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA

Kristen Beebea Phoenix Children’s Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA;b Mayo Clinic Arizona, Phoenix, Arizona, USA

Charlotte Schwalbacha Phoenix Children’s Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA

Kyrie Mageea Phoenix Children’s Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA

Roberta H. Adamsa Phoenix Children’s Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA;b Mayo Clinic Arizona, Phoenix, Arizona, USA

Alexander Ngwubea Phoenix Children’s Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA;b Mayo Clinic Arizona, Phoenix, Arizona, USACorrespondence[email protected]

https://orcid.org/0000-0003-4780-5642

show all

Abstract

Post-hematopoietic stem cell transplantation (HSCT) maintenance therapy using azacitidine and prophylactic donor lymphocyte infusions (DLI) was implemented for high-risk acute myeloid leukemia. Azacitidine was started on day +60 as a 5 day course every 28 days for 6 cycles. DLI was given every 6 weeks for 3 doses starting after day +120. Ten patients were treated on this protocol. With a 90% one-year disease free survival, we report this post-HSCT maintenance therapy is feasible, safe, and well tolerated.

Keywords:

Disclosure statement

There are no conflicts of interest to report.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia

Information for

Open access

Opportunities

Help and information

Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia

Abstract

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature